Home › Multiple Myeloma › District of Columbia › Washington
Multiple Myeloma clinical trials in Washington, DC
22 studies for Multiple Myeloma are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecruitingPhase 3
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
RecruitingObservational study
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RecruitingPhase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Tissue Collection for Studies of Lymph Cancer
RecruitingObservational study
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
RecruitingPhase 4
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi away
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecruitingPhase 3
- Center for Cancer and Blood Disorders, Bethesda · 7 mi away
18F-Fluciclovine PET/CT in Multiple Myeloma
RecruitingPhase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi away
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
RecruitingPhase 2
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
RecruitingObservational study
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RecruitingPhase 3
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RecruitingPhase 3
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
- GSK Investigational Site, Bethesda · 7 mi away
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RecruitingPhase 3
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Recruiting
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · 7 mi away
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RecruitingPhase 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · 7 mi away
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RecruitingPhase 3
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
RecruitingObservational studyHealthy volunteers welcome
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RecruitingPhase 3
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecruitingPhase 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA42 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- St. Louis, MO24 studies
- Rochester, MN24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Chicago, IL22 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.